The rising global incidence rates ofbreast cancer,coupled with the severe backlog of women requiringbreast cancer screeningappointments due to COVID-19, has reinforced the importance of women’s health and early detection of cancer. According to theWorld Health Organization(WHO), breast cancer has surpassed lung cancer as the most diagnosed cancer globally, with an estimated 2.3 million new cases and equating to 11.7% of all new cancers globally in 2020. Breast cancer also was responsible for just under 690,000 deaths globally in 2020.
As a result of the countable rise of breast cancer incidence globally, there is heightened pressures for government screening programs. However, screening programs alone are not sufficient to help tackle breast cancer mortality rates. It is essential that the accuracy of breast cancer detection is improved, while false positives and missed lesions are also reduced. These factors are forecast to be at the forefront of advancement in breast imaging for both screening and diagnosis.
Global drivers of thebreast imaging market包括加强对乳腺癌筛查项目益处的认识,以及提高乳腺癌检测准确性的必要性。这与以患者为中心的筛查方法和提高患者舒适度的技术进步一起,正在实施改进措施,以增加筛查项目的参与,这反过来推动了乳房x光造影设备的使用。
The world market for breast imaging equipment is forecast to reach almost $1.3 billion by 2024, and thebreast imaging artificial intelligence(AI) market is forecast to reach $205 million, according to a new report from Signify Research. However, the mammography and breast ultrasound market revenues declined by just under 15% and 18% respectively in 2020.
The Impact of COVID-19
COVID-19has severely impacted all medical procedures and healthcare facilities since the pandemic was declared globally in March 2020.Breast screening was significantly affected, with a high number of women missing scheduled mammograms. In the United States, the Centers for Disease Control and Prevention (CDC) reported in April 2020, as the country was largely shutting down, 80% fewer screening mammograms were conducted compared to the average number of mammograms in April in the previous five years. With such a significant population of women missing screening appointments, there is a big concern that many more women will develop later stages of breast cancer in coming years as a result. However, to help deal with the patient backlog, significant investment will be needed in both medical staff and breast imaging equipment. With increased pressure of screening centers and hospitals to address the number of women requiring breast cancer screening, there is heightened interest in how AI can be used to help prioritize scans, by highlighting suspected cases or lesions. Cases that are most urgent can then be addressed as a higher priority within the radiologists’ workflow and accelerate patient care pathways or protocols for further diagnosis.
Key Trends in Breast Imaging
Use of 2D vs 3D mammography in screening programs.The United States is the only country that currently uses 3-D mammography for screening, with all other countries only using this technology for diagnostic purposes. Western European countries are expected to be the next to adopt 3-D mammography screening programs, but this is not anticipated to happen until the next two to three years.
Changes in demographics of women being screened.Healthcare providers are considering changing breast cancer screening policies to include younger demographics to help reduce breast cancer related deaths and increase early detection. However, the possibility of overdiagnosis and false positives is still prevalent.
Personalized risk-based screening. The extensive number of factors which could contribute to the risk of breast cancer include genetics, family history, polygenic risk scores and high mammographic density. Personalized risk-based screening may also identify high-risk women for more intensive screening such asmagnetic resonance imaging(MRI) follow-up after mammography. Alternatively, low-risk women may be more suited to longer intervals between screening, which also reduces the risk of false positives through over-screening.
Use of multi-modality imaging for breast cancer screening.Movement towards risk-based screening is likely to encourage the use of multi-modality imaging. As women are segregated into groups, identified factors such as increased breast density are expected to facilitate supplemental screening that are not commonly practiced today.
Breast Cancer Screening Programs
There continues to be asignificant discrepancyacross the world with regard to screening programs. Countries with large populations, like China and India for example, do not have a formal, structured approach to screening. There are also large differences in participation even in regions where formal programs exist, such as in Western Europe. In Spain, Denmark and Finland there is around 80% participation, whereas participation rates in other countries like France, the DACH region (Germany-D, Austria-A, and Switzerland-CH) and Portugal are all significantly below the 50% mark. The European Union is attempting to increase participation and move the adoption rates to 80% or above.
Controlling False Positives
Mammograms will continue to play a fundamental role in the detection of breast cancers, but the occurrence offalse positives经常导致良性病变需要手术治疗。随着越来越多的女性有资格接受乳房x光检查,乳腺癌筛查项目面临着越来越大的压力,因此至关重要的是,假阳性的数量随后不会因此上升。乳房x线照相术筛查中的先进技术,如人工智能、切片合成引导活检、对比度增强光谱乳房x线照相术,以及更个性化的乳腺癌筛查方法,都有助于减少假阴性或阳性的数量,并推动更准确的乳腺癌早期检测。
Bhvita Jani is a senior analyst forSignify Research’s Medical Imagingteam. She is responsible for Signify Research’s X-ray market intelligence portfolio, including research on general radiography, fluoroscopy, breast iImaging, interventional and surgical X-ray, and the flat panel detector market. Jani hasexperience in market research for the X-ray, the medical and industrial flat panel detector markets, MRIand CT.
Related Breast Imaging Content:
COVID-19 Vaccine Can Cause False Positive Cancer Diagnosis
Help Spread Awareness of Potential COVID-19 Vaccine Imaging Side-effects
VIDEO: COVID Vaccine May Cause Enlarged Lymph Nodes on Mammograms— Interview with Constance "Connie" Lehman, M.D.
COVID-19 Vaccination Axillary Adenopathy Detected During Breast Imaging
VIDEO: COVID Vaccine Adenopathy Can Last Up to 10 Weeks— Interview with Yael Eshet, M.D.
VIDEO: Artificial Intelligence Trends in Medical Imaging— Interview with Signify Research
Technology Report: Artificial Intelligence in Radiology 2021
Related COVID-19 Cancer-care Information:
Female Breast Cancer Surpasses Lung as the Most Commonly Diagnosed Cancer Worldwide
Johns Hopkins Medicine Expert Weighs Devastating Impact of COVID-19 on Healthcare Workers